| scholarly article | Q13442814 |
| P50 | author | Guido Filler | Q39451597 |
| P2093 | author name string | Erin Elizabeth Kelland | |
| Leanne Michelle McAuley | |||
| P2860 | cites work | Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control | Q33783689 |
| Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria | Q37364926 | ||
| ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial | Q37563491 | ||
| Aldosterone blockade in chronic kidney disease: can it improve outcome? | Q37772047 | ||
| New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Characteristics and Usefulness of the Direct Renin Inhibitor Aliskiren | Q37777002 | ||
| Aliskiren binds to renin and prorenin bound to (pro)renin receptor in vitro. | Q42954961 | ||
| Strict blood-pressure control and progression of renal failure in children | Q43257210 | ||
| Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy | Q43961791 | ||
| Beta-trace protein, cystatin C, beta(2)-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children. | Q43972497 | ||
| Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy | Q44378923 | ||
| Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? | Q44550988 | ||
| Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators | Q48118604 | ||
| Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial | Q80688403 | ||
| Inhibition of the renin-angiotensin system in chronic kidney disease: a critical look to single and dual blockade | Q84513587 | ||
| Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? | Q94519175 | ||
| Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis | Q94691477 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 473-477 | |
| P577 | publication date | 2010-12-11 | |
| P1433 | published in | Pediatric Nephrology | Q15749796 |
| P1476 | title | Are we ready to use aliskiren in children? | |
| P478 | volume | 26 |
| Q33756874 | Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases |
| Q38087529 | Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options |
| Q82905378 | Not ready for prime time: aliskiren for treatment of hypertension or proteinuria in children |
Search more.